Lipella Pharmaceuticals Inc. - Common Stock (LIPO)
2.6200
+0.1100 (4.38%)
Lipella Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative therapies for urological conditions, particularly those affecting the bladder
The company is engaged in advancing its proprietary drug candidates through clinical trials, aiming to address unmet medical needs in the treatment of bladder diseases such as interstitial cystitis and overactive bladder. By leveraging advanced drug delivery technologies and focusing on targeted treatment approaches, Lipella seeks to improve patient outcomes and enhance the quality of life for individuals suffering from these debilitating conditions.
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Lipella's LP-310 Phase 2a trial showed strong efficacy and safety for oral lichen planus. The company plans a Phase 2b trial and an FDA designation request in 2025.
These five small-cap pharma and biotech stocks drew heavy attention on Stocktwits last week, driven by key trial results, FDA updates, and promising drug developments.
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.
